In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells
Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has s...
Saved in:
Published in: | Biological trace element research |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
30-04-2024
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1(NOXA), apoptotic protease activating factor 1 (APAF-1), Bcl-2-associated X protein (Bax), caspase-3, and caspase-9. In contrast, the expression of B cell lymphoma 2 (Bcl2), B cell lymphoma- extra-large (Bcl-xl), and microRNA-21 (miR-21), which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms. |
---|---|
AbstractList | Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid’s parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of
phorbol-12-myristate-13-acetate-induced protein 1
(
NOXA), apoptotic protease activating factor 1
(
APAF-1
),
Bcl-2-associated X protein
(
Bax), caspase-3,
and
caspase-9
. In contrast, the expression of
B cell lymphoma 2
(
Bcl2
),
B cell lymphoma‐ extra-large
(
Bcl-xl
), and
microRNA-21 (miR-21)
, which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms. Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1(NOXA), apoptotic protease activating factor 1 (APAF-1), Bcl-2-associated X protein (Bax), caspase-3, and caspase-9. In contrast, the expression of B cell lymphoma 2 (Bcl2), B cell lymphoma- extra-large (Bcl-xl), and microRNA-21 (miR-21), which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms. Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1(NOXA), apoptotic protease activating factor 1 (APAF-1), Bcl-2-associated X protein (Bax), caspase-3, and caspase-9. In contrast, the expression of B cell lymphoma 2 (Bcl2), B cell lymphoma- extra-large (Bcl-xl), and microRNA-21 (miR-21), which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms. |
Author | Seçme, Mücahit Dodurga, Yavuz Yıldırım, Onurcan Mete, Gülçin Abban Fenkci, Semin Melahat |
Author_xml | – sequence: 1 givenname: Onurcan orcidid: 0009-0006-2998-4877 surname: Yıldırım fullname: Yıldırım, Onurcan email: dronurcanyildirim@gmail.com organization: Department of Internal Medicine, Ege University School of Medicine, Izmir, 35100, Turkey. dronurcanyildirim@gmail.com – sequence: 2 givenname: Mücahit surname: Seçme fullname: Seçme, Mücahit organization: Department of Medical Biology, Ordu University School of Medicine, Ordu, Turkey – sequence: 3 givenname: Yavuz surname: Dodurga fullname: Dodurga, Yavuz organization: Department of Medical Biology, Pamukkale University School of Medicine, Denizli, Turkey – sequence: 4 givenname: Gülçin Abban surname: Mete fullname: Mete, Gülçin Abban organization: Department of Histology and Embriology, Pamukkale University School of Medicine, Denizli, Turkey – sequence: 5 givenname: Semin Melahat surname: Fenkci fullname: Fenkci, Semin Melahat organization: Department of Endocrinology and Metabolism, Pamukkale University School of Medicine, Denizli, Turkey |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38689139$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kMlOwzAURS1URAf4ARbISxYNeEocL0NUBqmAhApby_UggpI42Mmif09oC6u3uefqvjMHk9a3FoBLjG4wQvw2YoIwThBhCWI4zxN6AmY4TUWCOEETMEM4owkTOZuCeYxfCGFOBD0DU5pnucBUzIB9auFH1QcPV85Z3UfoHbzzodKw0JWBvoWlrWtY7nRtl7DofNf7WMUlVK2BTfX2UkRYtfDZmqGuVdjBzecu-JEsVatt2NPxHJw6VUd7cbwL8H6_2pSPyfr14aks1okmIu8TnDlndEbTjDjMU020M4ptqbMcc55lirMUMa0tSRW2RmlCUS7MGGQaGb2lC3B96O2C_x5s7GVTRT0uUK31Q5QUMcGx4CIfo-QQ1cHHGKyTXaia8QGJkfzVKw965ahX7vVKOkJXx_5h21jzj_z5pD9gcXZs |
Cites_doi | 10.1177/20420188211049611 10.3390/ijms23052805 10.1007/s12011-023-03864-0 10.3389/fendo.2021.708949 10.1155/2017/4915736 10.1016/j.canlet.2004.06.001 10.1007/s10534-014-9809-5 10.13201/j.issn.1001-1781.2018.22.018 10.3892/br.2016.747 10.1038/s41574-021-00470-9 10.1007/s12011-007-8081-8 10.1089/thy.2014.0335 10.1038/s41598-020-65207-6 10.1089/thy.2012.0045 10.1016/j.xphs.2020.04.015 10.1074/jbc.M114.619833 10.1016/j.yexmp.2017.10.002 10.1007/s004280000233 10.1007/s12011-019-01739-x 10.1016/j.humpath.2014.09.006 10.1038/cdd.2017.186 10.1371/journal.pone.0059639 10.2174/1568009618666180308105048 10.1002/bab.2233 10.1093/advances/nmz110 10.1016/j.biochi.2017.02.001 10.1016/j.jtemb.2022.126958 10.4238/gmr.15028300 10.1007/s12011-016-0824-y 10.1038/bjc.2014.157 10.3390/cells10040955 10.18632/oncotarget.15098 10.1016/j.jtemb.2022.127043 10.1007/s12011-018-1280-7 10.1016/j.jtemb.2022.126923 10.1039/b823234b 10.1016/j.canep.2014.05.001 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). |
Copyright_xml | – notice: 2024. The Author(s). |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1007/s12011-024-04188-3 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic PubMed |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1559-0720 |
ExternalDocumentID | 10_1007_s12011_024_04188_3 38689139 |
Genre | Journal Article |
GroupedDBID | --- -4W -56 -5G -BR -EM -~C -~X .86 .VR 06C 06D 0R~ 0VY 199 1N0 203 23N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 4.4 406 408 40D 40E 5GY 5VS 67N 6NX 78A 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHBH AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACGOD ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADNWM ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD B-. BA0 BBNVY BENPR BGNMA BHPHI CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBLON EBS EIOEI ESBYG F5P FERAY FFXSO FIGPU FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 HCIFZ HF~ HG6 HMJXF HRMNR HZ~ IJ- IKXTQ ITM IWAJR I~X I~Z J-C J0Z JBSCW JZLTJ KOV LLZTM M4Y M7P MA- NB0 NF0 NPM NPVJJ NQJWS NU0 O93 O9G O9I O9J P19 PF0 PT4 PT5 QOK QOR QOS R89 R9I RHV RNS ROL RPX RSV S16 S1Z S27 S3A S3B SAP SBL SBY SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 TSG TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR YZZ Z7U Z7V Z7W Z83 Z87 Z8O Z8P Z8Q Z91 ZMTXR ZOVNA ~02 ~A9 ~EX ~KM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c298t-16ffdc63562f175c2cfda4b3fe717766a74504cce25a1edac23089d5c24c0dcb3 |
ISSN | 0163-4984 |
IngestDate | Sat Oct 26 05:32:46 EDT 2024 Fri Nov 22 00:21:13 EST 2024 Sat Nov 02 12:20:55 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Boric acid miRNA TT cells Medullary thyroid cancer Cell cycle Apoptosis |
Language | English |
License | 2024. The Author(s). |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c298t-16ffdc63562f175c2cfda4b3fe717766a74504cce25a1edac23089d5c24c0dcb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0006-2998-4877 |
OpenAccessLink | https://link.springer.com/content/pdf/10.1007/s12011-024-04188-3.pdf |
PMID | 38689139 |
PQID | 3049719798 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3049719798 crossref_primary_10_1007_s12011_024_04188_3 pubmed_primary_38689139 |
PublicationCentury | 2000 |
PublicationDate | 2024-04-30 |
PublicationDateYYYYMMDD | 2024-04-30 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Biological trace element research |
PublicationTitleAlternate | Biol Trace Elem Res |
PublicationYear | 2024 |
References | WT Barranco (4188_CR15) 2004; 216 YH Feng (4188_CR33) 2016; 5 D Salvatore (4188_CR5) 2021; 17 C Mian (4188_CR31) 2012; 22 AS Acerbo (4188_CR14) 2009; 134 MA Bartz-Kurycki (4188_CR3) 2021; 12 SA Wells Jr (4188_CR1) 2015; 25 YH Chu (4188_CR30) 2017; 103 4188_CR16 LH Sun (4188_CR32) 2020; 10 E Cavedon (4188_CR34) 2017; 9 E Kahraman (4188_CR19) 2022; 73 A Lopalco (4188_CR37) 2020 F Galuppini (4188_CR7) 2021; 10 E Cebeci (4188_CR12) 2022; 70 J Kale (4188_CR20) 2018; 25 G Pennelli (4188_CR29) 2014; 46 M Sevimli (4188_CR11) 2022; 71 M Asadi (4188_CR17) 2022; 69 SE Kobylewski (4188_CR28) 2017; 176 F Faião-Flores (4188_CR23) 2013; 8 R Scorei (4188_CR13) 2008; 122 H Wang (4188_CR36) 2014; 111 P Li (4188_CR18) 2017; 8 H Khaliq (4188_CR22) 2018; 186 JZ Zhao (4188_CR2) 2018; 32 KA Henderson (4188_CR10) 2015; 28 FH Nielsen (4188_CR8) 2020; 11 4188_CR24 R Bagheri-Yarmand (4188_CR26) 2015; 290 R Shakeri (4188_CR27) 2017; 135 B Smolarz (4188_CR6) 2022; 23 4188_CR9 4188_CR4 R Hinze (4188_CR21) 2000; 437 RZ Morsi (4188_CR25) 2018; 18 L Yu (4188_CR35) 2014; 38 |
References_xml | – volume: 12 start-page: 204201882110496 year: 2021 ident: 4188_CR3 publication-title: Ther Adv Endocrinol Metab doi: 10.1177/20420188211049611 contributor: fullname: MA Bartz-Kurycki – volume: 23 start-page: 2805 issue: 5 year: 2022 ident: 4188_CR6 publication-title: Int J Mol Sci doi: 10.3390/ijms23052805 contributor: fullname: B Smolarz – ident: 4188_CR24 doi: 10.1007/s12011-023-03864-0 – ident: 4188_CR4 doi: 10.3389/fendo.2021.708949 – volume: 9 start-page: 4915736 year: 2017 ident: 4188_CR34 publication-title: Int J Endocrinol doi: 10.1155/2017/4915736 contributor: fullname: E Cavedon – volume: 216 start-page: 21 year: 2004 ident: 4188_CR15 publication-title: Cancer Lett doi: 10.1016/j.canlet.2004.06.001 contributor: fullname: WT Barranco – volume: 28 start-page: 133 issue: 1 year: 2015 ident: 4188_CR10 publication-title: Biometals doi: 10.1007/s10534-014-9809-5 contributor: fullname: KA Henderson – volume: 32 start-page: 1754 issue: 22 year: 2018 ident: 4188_CR2 publication-title: J Clin Otorhinolaryngol Head Neck Surg doi: 10.13201/j.issn.1001-1781.2018.22.018 contributor: fullname: JZ Zhao – volume: 5 start-page: 395 year: 2016 ident: 4188_CR33 publication-title: Biomed Rep doi: 10.3892/br.2016.747 contributor: fullname: YH Feng – volume: 17 start-page: 296 issue: 5 year: 2021 ident: 4188_CR5 publication-title: Nat Rev Endocrinol doi: 10.1038/s41574-021-00470-9 contributor: fullname: D Salvatore – volume: 122 start-page: 197 issue: 3 year: 2008 ident: 4188_CR13 publication-title: Biol Trace Elem Res doi: 10.1007/s12011-007-8081-8 contributor: fullname: R Scorei – volume: 25 start-page: 567 issue: 6 year: 2015 ident: 4188_CR1 publication-title: Thyroid doi: 10.1089/thy.2014.0335 contributor: fullname: SA Wells Jr – volume: 10 start-page: 8271 issue: 1 year: 2020 ident: 4188_CR32 publication-title: Sci Rep doi: 10.1038/s41598-020-65207-6 contributor: fullname: LH Sun – volume: 22 start-page: 890 year: 2012 ident: 4188_CR31 publication-title: Thyroid doi: 10.1089/thy.2012.0045 contributor: fullname: C Mian – year: 2020 ident: 4188_CR37 publication-title: J Pharm Sci doi: 10.1016/j.xphs.2020.04.015 contributor: fullname: A Lopalco – volume: 290 start-page: 11749 year: 2015 ident: 4188_CR26 publication-title: J Biol Chem doi: 10.1074/jbc.M114.619833 contributor: fullname: R Bagheri-Yarmand – volume: 103 start-page: 229 year: 2017 ident: 4188_CR30 publication-title: Exp Mol Pathol doi: 10.1016/j.yexmp.2017.10.002 contributor: fullname: YH Chu – volume: 437 start-page: 256 year: 2000 ident: 4188_CR21 publication-title: Virchows Arch doi: 10.1007/s004280000233 contributor: fullname: R Hinze – ident: 4188_CR9 doi: 10.1007/s12011-019-01739-x – volume: 46 start-page: 50 year: 2014 ident: 4188_CR29 publication-title: Hum Pathol doi: 10.1016/j.humpath.2014.09.006 contributor: fullname: G Pennelli – volume: 25 start-page: 65 issue: 1 year: 2018 ident: 4188_CR20 publication-title: Cell Death Differ doi: 10.1038/cdd.2017.186 contributor: fullname: J Kale – volume: 8 issue: 3 year: 2013 ident: 4188_CR23 publication-title: PLoS ONE doi: 10.1371/journal.pone.0059639 contributor: fullname: F Faião-Flores – volume: 18 start-page: 914 issue: 10 year: 2018 ident: 4188_CR25 publication-title: Curr Cancer Drug Targets doi: 10.2174/1568009618666180308105048 contributor: fullname: RZ Morsi – volume: 69 start-page: 1633 issue: 4 year: 2022 ident: 4188_CR17 publication-title: Biotechnol Appl Biochem doi: 10.1002/bab.2233 contributor: fullname: M Asadi – volume: 11 start-page: 461 issue: 2 year: 2020 ident: 4188_CR8 publication-title: Adv Nutr doi: 10.1093/advances/nmz110 contributor: fullname: FH Nielsen – volume: 135 start-page: 111 year: 2017 ident: 4188_CR27 publication-title: Biochimie doi: 10.1016/j.biochi.2017.02.001 contributor: fullname: R Shakeri – volume: 71 year: 2022 ident: 4188_CR11 publication-title: J Trace Elem Med Biol doi: 10.1016/j.jtemb.2022.126958 contributor: fullname: M Sevimli – ident: 4188_CR16 doi: 10.4238/gmr.15028300 – volume: 176 start-page: 278 issue: 2 year: 2017 ident: 4188_CR28 publication-title: Biol Trace Elem Res doi: 10.1007/s12011-016-0824-y contributor: fullname: SE Kobylewski – volume: 111 start-page: 339 year: 2014 ident: 4188_CR36 publication-title: Br J Cancer doi: 10.1038/bjc.2014.157 contributor: fullname: H Wang – volume: 10 start-page: 955 issue: 4 year: 2021 ident: 4188_CR7 publication-title: Cells doi: 10.3390/cells10040955 contributor: fullname: F Galuppini – volume: 8 start-page: 23996 issue: 14 year: 2017 ident: 4188_CR18 publication-title: Oncotarget. doi: 10.18632/oncotarget.15098 contributor: fullname: P Li – volume: 73 year: 2022 ident: 4188_CR19 publication-title: J Trace Elem Med Biol doi: 10.1016/j.jtemb.2022.127043 contributor: fullname: E Kahraman – volume: 186 start-page: 226 issue: 1 year: 2018 ident: 4188_CR22 publication-title: Biol Trace Elem Res doi: 10.1007/s12011-018-1280-7 contributor: fullname: H Khaliq – volume: 70 year: 2022 ident: 4188_CR12 publication-title: J Trace Elem Med Biol doi: 10.1016/j.jtemb.2022.126923 contributor: fullname: E Cebeci – volume: 134 start-page: 1669 issue: 8 year: 2009 ident: 4188_CR14 publication-title: Analyst doi: 10.1039/b823234b contributor: fullname: AS Acerbo – volume: 38 start-page: 408 year: 2014 ident: 4188_CR35 publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2014.05.001 contributor: fullname: L Yu |
SSID | ssj0017293 |
Score | 2.421883 |
Snippet | Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its... Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid’s parafollicular C cells. Due to its... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
Title | In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38689139 https://search.proquest.com/docview/3049719798 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Ja9tAFB6c5NJLaZsuThemUHpRBNZiLUdZkVND4kCjlOQkpJkRESQjo6Xg_vq-WSw1LYX0UDCSPXje4b2PN28fhD6VLvOsglhmYYfMdH1KzMILA7MEaxlOF7AomLzE9tJfXwcniZtMJrs6rnHtv0oa1kDWonP2H6Q9EIUF-A4yhydIHZ6PkvuKG9-qrqmNZKzUWIhBIEZEKipyA7EI18VbogqJo0296epWjRoQUfT76us6klWy53AMAUqarZHebpsadscCI42k0D5IB1eDDu2aHFQFU1Xphp4lNMScb4TxurDuqHo36iUxecH7hoxYvWQyh--rW9zPxY9FTPLbaqjTOalp36i48E3-vf8xYIepK_9O1Z47RUfEdYpC09dhDtv9JWPDtGqei3Yr2Tr3p-Kf6UZoFfKV2y1AhjMec7vU_voiW16dnWVpcp3uoQMbFBTox4NolZ4uh_wTuByObrFSjZa_031oxvzFN5E2SvoMPdXOBY4UKp6jCeMv0GHE866-3-LPWJb7yjzKIWIrjiVQsAYKrkssgYIFUHDNsRAzlkA5xgNMjjGABCuQ4IrjASRYgwQrkMjd7Ut0tUzS-Iup79wwiR0GnWl5ZUmJGFpol2BZEpuUNHcLp2Tg9_uel_vufOYSwux5bjGaE3Bhg5DCH10yo6RwXqF9XnP2BuHZjPrgLtg0CHK3LJyQEFLOHfEpbLDsp8jYsTDbqNEq2ThEWzA8A4ZnkuGZM0Ufd1zOQAOKtFbOWd23mUgU-1boh8EUvVbsH-g5gSfy8OHRI3a_RU9G4L1D-13Ts_dor6X9Bw2Pn8Iae6w |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Springer Nature |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+Vitro+Effects+of+Boric+Acid+on+Cell+Cycle%2C+Apoptosis%2C+and+miRNAs+in+Medullary+Thyroid+Cancer+Cells&rft.jtitle=Biological+trace+element+research&rft.au=Y%C4%B1ld%C4%B1r%C4%B1m%2C+Onurcan&rft.au=Se%C3%A7me%2C+M%C3%BCcahit&rft.au=Dodurga%2C+Yavuz&rft.au=Mete%2C+G%C3%BCl%C3%A7in+Abban&rft.date=2024-04-30&rft.eissn=1559-0720&rft_id=info:doi/10.1007%2Fs12011-024-04188-3&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-4984&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-4984&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-4984&client=summon |